Clàudia Resa Parés
Investigador pre-doc
Research group
BSc Biochemistry (2019). Master in drug Research, Control and Developement (2020) Universidad de Barcelona.
Professional network profiles
Last Publications
- Aschero MR, Castillo H, Baulenas-Farrés M, Resa-Parés C, Jiménez-Cabaco A, Rodriguez E, Monterrubio C, Pérez-Jaume S, Suñol M, Chantada G, Lavarino C, Mora J and Carcaboso AM Prognostic value of xenograft engraftment in patients with metastatic high-risk neuroblastoma PEDIATRIC BLOOD & CANCER . 70(6): .
- Pascual-Pastó G, Resa-Parés C, Castillo H, Aschero MR, Baulenas-Farrés M, Vilà-Ubach M, Burgeño-Sandoval V, Balaguer-Lluna L, Cuadrado-Vilanova M, Gene-Olaciregui N, Martinez N, Pérez-Jaume S, de Alava, E, Tirado, OM, Lavarino C, Mora J and Carcaboso AM Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma BIOCHEMICAL PHARMACOLOGY . 208: 115408-115408.
- Pascual-Pastó G, Castillo H, Unceta N, Aschero MR, Resa-Parés C, Gómez-Caballero A, Vilà-Ubach M, Muñoz-Aznar O, Suñol M, Burgeño-Sandoval V, Gomez-Gonzalez S, Sosnik A, Ibarra M, Schaiquevich P, de Álava E, Tirado OM, Mora J and Carcaboso AM SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas JOURNAL OF CONTROLLED RELEASE . 342: 81-92.
Projects
- Project name:
- Immune microenvironment of retinoblastoma
- Leader
- Angel Montero Carcaboso
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI21/00216
- Starting - finishing date:
- 2022 - 2026
- Project name:
- SGR 2022-2024_Grup de recerca en tumors del desenvolupament
- Leader
- Jaume Mora Graupera
- Funding entities:
- Agaur - Agència de Gestió d'Ajuts Universitaris i de Recerca
- Code
- 2021 SGR 01612
- Starting - finishing date:
- 2022 - 2025
News
-
Gate2Brain Receives EMA Orphan Drug Designation for Its Groundbreaking Pediatric Cancer Treatment
Gate2Brain, has reached a major milestone in the fight against pediatric brain tumors by obtaining Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) for its innovative product, G2B-002.
-
Gate2Brain recognized by the Wild Card program at Pediatric Innovation Day
The Wild Card program in the field of pediatrics, powered by EIT Health and the pediatric innovation hub i4KIDS, has selected the start-up Gate2Brain to participate in its acceleration program.
-
Researchers at IRSJD develop a method to predict the efficacy of a potent nanomedicine in a severe childhood cancer
Researchers at IRSJD have developed a method that predicts the anticancer efficacy of nab-paclitaxel, a well-known nanomedicine, in mouse models, for treatment of Ewing sarcoma, a severe cancer affecting the bones and soft tissue of children and adolescents.